QCG
CRNX icon

Quadrant Capital Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Quadrant Capital Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.35K Hold
230
– – ﹤0.01% 2235
2025
Q4 		$10.7K Hold
230
– – ﹤0.01% 2187
2025
Q3 		$9.58K Buy
+230
New +$7.35K ﹤0.01% 2176
2025
Q1 		– Sell
-267
Closed -$13.7K – 2758
2024
Q4 		$13.7K Hold
267
– – ﹤0.01% 2030
2024
Q3 		$13.6K Hold
267
– – ﹤0.01% 2044
2024
Q2 		$12K Hold
267
– – ﹤0.01% 2056
2024
Q1 		$12.5K Buy
+267
New +$10.4K ﹤0.01% 2023

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Quadrant Capital Group's CRNX Position: Q1 2026 in Review

Quadrant Capital Group held its Crinetics Pharmaceuticals (CRNX) position steady in Q1 2026 at 230 shares worth $8.35K. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

Quadrant Capital Group first reported a position in CRNX in Q1 2024 and has held it in 7 quarters since. The position peaked at $13.7K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Quadrant Capital Group held 230 shares of Crinetics Pharmaceuticals worth $8.35K as of Q1 2026.
  • Quadrant Capital Group left its Crinetics Pharmaceuticals share count unchanged in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2235 holding.
  • Quadrant Capital Group first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Quadrant Capital Group's Crinetics Pharmaceuticals position peaked at $13.7K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.